An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.
EpiSwitch Prostate Screening blood test launches on US market
The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
CMS grants Transitional Pass-Through payment status to flotufolastat F 18
The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Postoperative Urinary Retention – AUGS Publications Committee Interview
Dr. Kate Meriwether, AUGS Publications Committee member, interviews Dr Colleen McDermott, the first author of the Clinical Consensus Statement “Postoperative Urinary Retention,” to provide an overview and highlight the findings of the document.
Academic Career Mentoring Program Application Deadline: October 20, 2023
AUGS is seeking both interested mentors and mentees who are looking for a mutually rewarding mentorship experience.
2 Clarke Drive Cranbury, NJ 08512